NT-501, the lead product candidate of Neurotech Pharmaceutisals, inc., have successfully slowed down the loss of vision in a Phase 2 clinical trial, in patients suffering from macular degeneration along with geographic atrophy(GA). GA is a condition that destroys sharp central vision and causes serious vision loss to one or both eyes.
Latest report shows that, age-related macular degeneration (AMD) is the leading cause of severe vision loss in United States and most Western countries. And this report drives the US researchers to conduct a major study across the United States to help the doctors to identify the factor that help in developing AMD. This in turn will help the doctors to identify the patient who are most vulnerable to advanced age-related macular degeneration (AMD).